Homepage
Full 18-step deep-dive · ~20–30 min · a member feature.
No report run on this ticker yet
Only preliminary foundational data below
Sign in to run a fresh report
Free · results in ~10 min
For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Option Care Health Inc. (OPCH) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Option Care Health Inc.
OPCH NASDAQ
Healthcare · Medical Care Facilities
Bannockburn, IL 60015, United States
optioncarehealth.com
Price
$24.07
Market Cap
$3.6B
Employees
8,000
Beta
0.61
Avg Volume
2,459,819
CEO
Mr. John Charles Rademacher
Option Care Health Inc. operates as a healthcare services company, primarily engaged in providing infusion therapy and other related services. Its core function revolves around delivering comprehensive care through its network of facilities, home-based services, and care management programs. Option Care Health Inc. specializes in treatments for critical illnesses such as immune disorders, cancer, and chronic conditions, offering personalized care plans tailored to individual patient needs. This company is instrumental in the health services sector, bridging the gap between hospitals and home-based care, which is crucial for patient recovery and ongoing treatment. With a strong emphasis on clinical expertise and patient-focused care, Option Care Health Inc. stands out in the healthcare market, addressing the growing demand for specialty medications and the need for integrated healthcare solutions. Its services are essential for enhancing patient outcomes and managing complex health conditions outside traditional hospital settings.
Runs with full report
Earnings Schedule
Checked daily · calendar updated Aug 14 No upcoming print on the calendar yet — companies typically confirm a few weeks ahead. Last print was Jul 29, 2026.
EPS surprise history — vs analyst consensus · 5 prints of vendor history
+2.5%
Jul '25
+4.7%
Oct '25
-2.1%
Feb '26
+8.1%
Apr '26
+4.7%
Jul '26
| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| Jul 29, 2026 | $0.43 | $0.45 +4.7% | — | — |
| Apr 30, 2026 | $0.37 | $0.40 +8.1% | — | — |
| Feb 24, 2026 | $0.47 | $0.46 -2.1% | — | — |
| Oct 30, 2025 | $0.43 | $0.45 +4.7% | — | — |
| Jul 30, 2025 | $0.40 | $0.41 +2.5% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
| Filed | Form | Document |
|---|---|---|
| Jul 29, 2026 | 10-Q | View |
| Jul 29, 2026 | 8-K | View |
| Jul 8, 2026 | 4 | View |
| Jul 8, 2026 | 3 | View |
| May 22, 2026 | 4 | View |
| May 22, 2026 | 4 | View |
| May 22, 2026 | 4 | View |
| May 22, 2026 | 4 | View |
| May 22, 2026 | 4 | View |
| May 22, 2026 | 4 | View |
| May 22, 2026 | 4 | View |
| May 22, 2026 | 4 | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Last updated: Aug 14, 2026 8:29am (just now)
Current data · timestamped when a report runs
$24.07
Change · Aug 14
+0.23 (+0.96%)
Day Range
$23.90 – $24.27
52-Week Range
$18.01 – $36.80
50-Day MA
$21.96
200-Day MA
$27.51
Volume
1,259,480.00
Share Structure
Outstanding
149,777,268.00
Float
138,049,569.00
Free Float
92.2%
High free float
— 92.2% of shares trade freely, ~7.8% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
TD Twelve Data statement
HEX SEC filing
P/E Ratio (Price per dollar of earnings)
HEXStock Price / EPS (Diluted)
18.95
Stock Price: $24.07
EPS (Diluted): 1.27
EPS (Diluted): 1.27
P/B Ratio (Price vs net asset value)
HEXStock Price / Book Value Per Share
2.96
Stock Price: $24.07
Total Equity: $1.33B
Shares: 163,365,000
Total Equity: $1.33B
Shares: 163,365,000
EV/EBITDA (Total value vs operating profit)
HEXEnterprise Value / EBITDA
11.59
Market Cap: $3.61B
Total Debt: $1.16B
Cash: $232.62M
EBITDA: $405.44M
Total Debt: $1.16B
Cash: $232.62M
EBITDA: $405.44M
Enterprise Value (Takeover price (cap + debt - cash))
HEXMarket Cap + Total Debt - Cash
$4.7B
Market Cap: $3.61B
Total Debt: $1.16B
Cash: $232.62M
Total Debt: $1.16B
Cash: $232.62M
Gross Margin (Revenue left after direct costs)
HEXGross Profit / Revenue
19.3%
Gross Profit: $1.09B
Revenue: $5.65B
Revenue: $5.65B
Operating Margin (Revenue left after all operations)
HEXOperating Income / Revenue
6.0%
Operating Income: $337.91M
Revenue: $5.65B
Revenue: $5.65B
Net Margin (Revenue left as actual profit)
HEXNet Income / Revenue
3.7%
Net Income: $207.59M
Revenue: $5.65B
Revenue: $5.65B
ROE (Profit from shareholder equity)
HEXNet Income / Total Equity
15.7%
Net Income: $207.59M
Total Equity: $1.33B
Total Equity: $1.33B
ROIC (Profit from all invested capital)
HEXNOPAT / Invested Capital
11.0%
Operating Income: $337.91M
Tax Rate: 26.6%
Equity: $1.33B
Total Debt: $1.16B
Cash: $232.62M
Tax Rate: 26.6%
Equity: $1.33B
Total Debt: $1.16B
Cash: $232.62M
Current Ratio (Can it pay short-term bills)
HEXCurrent Assets / Current Liabilities
1.53
Current Assets: $1.26B
Current Liabilities: $829.35M
Current Liabilities: $829.35M
Debt/Equity (Leverage — debt vs equity)
HEXTotal Debt / Total Equity
0.88
Short-Term Debt: $6.78M
Long-Term Debt: $1.15B
Total Debt: $1.16B
Total Equity: $1.33B
Long-Term Debt: $1.15B
Total Debt: $1.16B
Total Equity: $1.33B
Rev/Share (Top-line per share)
HEXRevenue / Shares Outstanding
$34.58
Revenue: $5.65B
Shares: 163,365,000
Shares: 163,365,000
Book Value/Share (Net assets per share)
HEX(Total Assets - Total Liabilities) / Shares
$8.12
Total Equity: $1.33B
Shares: 163,365,000
Shares: 163,365,000
FCF/Share (Real cash generated per share)
HEX(Operating Cash Flow + CapEx) / Shares
$1.33
Operating CF: $258.45M
CapEx: -$41.31M
Shares: 163,365,000
CapEx: -$41.31M
Shares: 163,365,000
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
TDLast Annual Dividend / Stock Price
—
Last Dividend: $0.00
Stock Price: $24.07
Stock Price: $24.07
Payout Ratio (Earnings paid out as dividends)
HEXDividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: $207.59M
Net Income: $207.59M
Dividends paid not available in cash flow statement
Income Statement (Annual)
Last updated: Aug 8, 2026 5:24am (6d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $3.4B | $3.9B | $4.3B | $4.9B | $5.6B |
| Cost of Revenue | $2.7B | $3.1B | $3.3B | $3.9B | $4.6B |
| Gross Profit | $779.6M | $866.9M | $981.2M | $1.0B | $1.1B |
| Operating Expenses | $588.8M | $626.7M | $666.6M | $691.2M | $750.0M |
| Operating Income | $190.8M | $240.2M | $314.6M | $321.8M | $337.9M |
| Net Income | $139.9M | $150.6M | $267.1M | $211.8M | $207.6M |
| EBITDA | $253.9M | $300.8M | $373.8M | $382.7M | $405.4M |
| EPS | $0.78 | $0.83 | $1.49 | $1.23 | $1.28 |
| EPS (Diluted) | $0.77 | $0.83 | $1.48 | $1.23 | $1.27 |
Balance Sheet (Annual)
Last updated: Aug 8, 2026 5:24am (6d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $119.4M | $294.2M | $343.8M | $412.6M | $232.6M |
| Total Current Assets | $710.3M | $994.3M | $1.1B | $1.3B | $1.3B |
| Total Assets | $2.8B | $3.1B | $3.2B | $3.4B | $3.5B |
| Current Liabilities | $459.7M | $565.4M | $618.3M | $780.1M | $829.3M |
| Long-Term Debt | $1.1B | $1.1B | $1.1B | $1.1B | $1.2B |
| Total Liabilities | $1.6B | $1.7B | $1.8B | $2.0B | $2.1B |
| Total Equity | $1.2B | $1.4B | $1.4B | $1.4B | $1.3B |
| Retained Earnings | $39.9M | $190.4M | $457.5M | $669.3M | $876.9M |
Cash Flow (Annual)
Last updated: Aug 8, 2026 5:24am (6d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $208.6M | $267.5M | $371.3M | $323.4M | $258.4M |
| Capital Expenditure | -$25.6M | -$35.4M | -$41.9M | -$35.6M | -$41.3M |
| Free Cash Flow | $182.9M | $232.2M | $329.4M | $287.8M | $217.1M |
| Acquisitions (net) | -$85.9M | -$87.4M | -$12.5M | $0 | -$117.2M |
| Net Debt Issued / (Repaid) | $855.1M | $0 | $0 | $50.0M | $229.5M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | -$250.3M | -$252.7M | -$310.0M |
| Net Change in Cash | $20.2M | $174.8M | $49.7M | $68.7M | -$179.9M |
Growth Trends (YoY %)
Last updated: Aug 8, 2026 5:24am (6d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +14.7% | +9.1% | +14.2% | +15.0% |
| Gross Profit Growth | +11.2% | +13.2% | +3.2% | +7.4% |
| Operating Income Growth | +25.9% | +31.0% | +2.3% | +5.0% |
| Net Income Growth | +7.6% | +77.4% | -20.7% | -2.0% |
| EBITDA Growth | +18.5% | +24.3% | +2.4% | +5.9% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-07-06 | Bhatia Prateek | A-Award | 16,386.00 | $0.00 | $0 |
| 2026-07-06 | Bhatia Prateek | A-Award | 23,409.00 | $0.00 | $0 |
| 2026-05-20 | Bierbower Elizabeth D | A-Award | 8,997.00 | $0.00 | $0 |
| 2026-05-20 | Deckmann Natasha | A-Award | 8,997.00 | $0.00 | $0 |
| 2026-05-20 | Deckmann Natasha | A-Award | 844.00 | $22.23 | $18,762 |
| 2026-05-20 | KRAEMER HARRY M JANSEN JR | A-Award | 8,997.00 | $0.00 | $0 |
| 2026-05-20 | KRAEMER HARRY M JANSEN JR | A-Award | 12,079.00 | $22.23 | $268,516 |
| 2026-05-20 | Pate R Carter | A-Award | 8,997.00 | $0.00 | $0 |
| 2026-05-20 | SULLIVAN TIMOTHY P | A-Award | 8,997.00 | $0.00 | $0 |
| 2026-05-20 | SULLIVAN TIMOTHY P | A-Award | 4,836.00 | $22.23 | $107,504 |
| 2026-05-20 | Bodem Barbara W. | A-Award | 8,997.00 | $0.00 | $0 |
| 2026-05-20 | Wright Norman L. | A-Award | 8,997.00 | $0.00 | $0 |
| 2026-05-20 | BRANDT ERIC | A-Award | 8,997.00 | $0.00 | $0 |
| 2026-05-20 | BRANDT ERIC | A-Award | 2,643.00 | $22.23 | $58,754 |
| 2026-05-19 | Smyser Collin | M-OptionExercise | 812.00 | $0.00 | $0 |
| 2026-05-19 | Smyser Collin | F-InKind | 360.00 | $20.86 | $7,510 |
| 2026-05-07 | SULLIVAN TIMOTHY P | P-Purchase | 24,154.00 | $20.69 | $499,671 |
| 2026-05-04 | Sethna Meenal | P-Purchase | 16,225.00 | $20.16 | $327,075 |
| 2026-05-04 | RADEMACHER JOHN CHARLES | P-Purchase | 12,500.00 | $21.18 | $264,706 |
| 2026-05-04 | KRAEMER HARRY M JANSEN JR | P-Purchase | 36,610.00 | $21.41 | $783,773 |
Industry Benchmarks
Compares OPCH against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
Not applicable for this companies
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
Not applicable for this companies
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
Not applicable for this companies
4h
Dividend Discount Model
— For dividend/income stocks only
Not applicable for this companies
4i
Book Value Analysis
— For deep value / turnaround stocks only
Not applicable for this companies
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
Not applicable for this companies
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for OPCH — it's generated by the pipeline (
market-narrative step).
Claude Reading
No AI findings yet for OPCH — they're generated by the
pipeline (
ai-findings step) when a report is run on this ticker.
GPT Reading
No GPT reading yet for OPCH — it's generated by the
pipeline (
gpt-critique step) after the other Big-3 seats, when a
report is run on this ticker.
Grok Reading
No Grok reading yet for OPCH — it's generated by the
pipeline (
grok-critique step) alongside the other Big-3 seats, when a
report is run on this ticker.
Advanced Analysis Forensic deep-dive · four lenses
No community reviews yet for OPCH.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · twelvedata
v1.1.532 · 1ec19de8 · 2026-08-13 17:53:37